European regulators suspended the approval of Pfizer Inc.’s sickle cell anemia drug, Oxbryta, citing a higher rate of disease ...

Pfizer is withdrawing all of its sickle cell disease drug, Oxbryta, worldwide because of safety concerns. Pfizer ( PFE) ...

Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and ...

The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...

U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where ...

Pfizer is pulling its sickle cell disease (SCD) treatment voxelotor (Oxbryta) from global markets after data review showed an ...

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...

The company said benefits no longer outweighed the risks, with data suggesting the drug might increase the risk of pain ...

The US big pharma company Pfizer has voluntarily withdrawn the oral sickle cell disease treatment Oxbryta from the market and ...

Pfizer had big hopes for a sickle-cell disease drug, as did those suffering from the disease. Things didn't turn out as ...

The withdrawal comes as trial results indicate safety concerns with the drug, Oxbryta, which was first approved in the U.S.